Zika Virus Infections – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Zika Virus Infections – Pipeline Review, H2 2019’, provides an overview of the Zika Virus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Zika Virus Infections

The report reviews pipeline therapeutics for Zika Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Zika Virus Infections therapeutics and enlists all their major and minor projects

The report assesses Zika Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Zika Virus Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Zika Virus Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Zika Virus Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Activirosomes Ltd

Acuitas Therapeutics Inc

AIM ImmunoTech Inc

Aravive Inc

Bharat Biotech Ltd

Biken Co Ltd

BioCryst Pharmaceuticals Inc

BioNet- Asia Co Ltd

Biotron Ltd

BravoVax Co Ltd

CanSino Biologics Inc

Chugai Pharmaceutical Co Ltd

Cidara Therapeutics Inc

Ciloa

Clayton Biotechnologies Inc

Cocrystal Pharma Inc

Codagenix Inc

Emergent BioSolutions Inc

Emergex Vaccines Ltd

Ennaid Therapeutics LLC

Enyo Pharma SA

Etubics Corp

Excivion Ltd

Future Medicine Co Ltd

GeneOne Life Science Inc

GeoVax Labs Inc

Greffex Inc

GT Biopharma Inc

Hawaii Biotech Inc

Heat Biologics Inc

HSRx Group

Humabs BioMed SA

IDBiologics Inc

Immunomodulation Inc

Imutex Ltd

IMV Inc

Inmunova SA

Inovio Pharmaceuticals Inc

Johnson & Johnson

KM Biologics Co Ltd

Macrophage Therapeutics Inc

Medigen Inc

Microbiotix Inc

Moderna Therapeutics Inc

Mymetics Corp

NanoViricides Inc

Novalex Therapeutics Inc

Palisades Therapeutics

Pharos Biologicals LLC

Phoenix Biotechnology Inc

Plex Pharmaceuticals Inc

Precision Virologics Inc

Prokarium Ltd

ProtInhi BV

Quratis Inc

Replikins Ltd

Riboscience LLC

Sanofi

Sementis Ltd

Spotlight Innovation Inc

Stabilitech Biopharma Ltd

Starpharma Holdings Ltd

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

Themis Bioscience GmbH

Theravectys SA

Tiba Biotech LLC

Tychan Pte Ltd

Valneva SE

VBI Vaccines Inc

VenatoRx Pharmaceuticals Inc

Virocovax

Xenothera SAS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Zika Virus Infections Overview 6

Zika Virus Infections Therapeutics Development 7

Zika Virus Infections Therapeutics Assessment 20

Zika Virus Infections Companies Involved in Therapeutics Development 28

Zika Virus Infections Drug Profiles 46

Zika Virus Infections Dormant Projects 176

Zika Virus Infections Discontinued Products 177

Zika Virus Infections Product Development Milestones 178

Appendix 189

List of Tables

List of Tables

Number of Products under Development for Zika Virus Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Zika Virus Infections – Pipeline by Activirosomes Ltd, H2 2019

Zika Virus Infections – Pipeline by Acuitas Therapeutics Inc, H2 2019

Zika Virus Infections – Pipeline by AIM ImmunoTech Inc, H2 2019

Zika Virus Infections – Pipeline by Aravive Inc, H2 2019

Zika Virus Infections – Pipeline by Bharat Biotech Ltd, H2 2019

Zika Virus Infections – Pipeline by Biken Co Ltd, H2 2019

Zika Virus Infections – Dormant Projects, H2 2019

Zika Virus Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Zika Virus Infections – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Zika Virus Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports